Trial Profile
Retrospective study, Evaluating Efficacy and Safety of cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC) in second and later lines
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2016
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 09 Aug 2016 New trial record